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Description of the evidence collection method 
A literature review of relevant scientific articles was performed 
in the MEDLINE database. The search was conducted in actual 
clinical scenarios and included the key words (MeSH terms): 
Anti-Inflammatory Agents, Non-Steroidal AND Dysmenorrhea.
Degree of recommendation and strength of evidence
A:  Experimental or observational studies of higher consistency
B:  Experimental or observational studies of lesser consistency
C:  Case reports (non-controlled studies)
D:  Opinions without critical evaluation, based on consensuses, 
physiological studies, or animal models
Objective
To evaluate the benefits and the risks of primary dysmenorrhea 
treatment with anti-inflammatory drugs. 
Introduction
Dysmenorrhea is one of the most prevalent gynecological 
problems among adolescents and young adults, whose 
condition is usually primary and not caused by any pelvic 
pathology1 (B). It affects approximately 50% of women 
of reproductive age, and in 10% of them the symptoms 
are sufficiently intense to interfere with daily life2 (B). It is 
believed that the underlying cause of primary dysmenorrhea 
is the over-production of uterine prostaglandins, derived from 
cyclooxygenase-2 (COX-2) activity3 (B)4 (D). 
Primary dysmenorrhea is clinically characterized as colic 
pain in the lower abdomen in the beginning of the menstrual 
period that may continue for a few days, in the absence of 
any pelvic pathology. The etiology of primary dysmenorrhea 
is yet to be well understood, although many of the symptoms 
may be explained by prostaglandin action, particularly PGF2a, 
present in menstrual fluid, which causes abnormal uterine 
activity, reducing blood flow to the uterus and sensitizing 
nociceptors3 (B). This explanation originates from the 
observation that women with primary dysmenorrhea have 
higher levels of prostaglandin in the endometrium and 
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menstrual blood, with significant symptom improvement 
as prostaglandin levels decrease2 (B). Thus, prostaglandin 
production inhibition in the endometrium, with the use of 
nonsteroidal anti-inflammatory drugs (NSAIDs), is a rational 
and effective treatment of primary dysmenorrhea5,6 (A).
The synthesis of prostaglandins in humans is performed 
by two types of cyclooxygenases (COX), COX-1 and COX-2, 
which have different functions7 (B). COX-1 is constitutively 
expressed in many tissues, such as platelets, and is related 
to the maintenance of the gastrointestinal mucosal integrity. 
COX-2, found with limited expression in basal conditions, 
undergoes up-regulation by several inflammatory mediators, 
and it is related to colorectal carcinogenesis8,9 (D). The activity 
of non-steroidal anti-inflammatory drugs is related to COX-2 
inhibition, and also determines COX-1 inhibition, therefore 
causing alterations in platelet function and predisposing 
patients to adverse gastrointestinal events. Thus, selective 
COX-2 inhibitors standout as drugs with an anti-inflammatory 
action that are effective against pain, and related to less 
adverse events7 (B).
An important aspect to be considered regarding the use of 
anti-inflammatory drugs is related to their safety, especially 
for long-term use, as, for instance, in their prescription as 
part of a strategy to control inflammation and pain associated 
with osteoarthritis or rheumatoid arthritis, due to severe 
cardiovascular events involved, such as acute myocardial 
infarction, unstable angina, and venous thromboembolic 
events10 (D). The mechanisms by which these events occur 
are not fully understood, but a few possibilities have been 
suggested, such as fluid retention caused by the inhibition 
of renal prostanoid synthesis (PGI2 and PGE2); reduction 
in PGI2  production by the vascular endothelium, which 
determines an increase in cardiovascular risk; and promotion of 
atherogenesis or atherosclerotic plaque destabilization11,12 (D).
A multicenter randomized study using a selective COX-2 
inhibitor (rofecoxib 25 mg/day) as the drug indicated for 
the chemoprevention of adenomatous colonic polyps 
was interrupted during follow-up, due to the increase in 
cardiovascular events associated with its use (2.6% vs. 4.6% 
for the control group and after treatment with rofecoxib, 
respectively, presenting hazard ratio (HR) = 1.79, 95% CI: 
1.17 to 2.73)13 (A).
Another multicenter study, designed to evaluate the 
cardiovascular safety and gastrointestinal tolerability of 
etoricoxib at oral doses of 60 or 90 mg/day and diclofenac 
at a dose of 150 mg/day in osteoarthritis patients for a 
mean period of 20 months, observed that the occurrence 
of cardiovascular events was similar both with the use of 
selective COX-2 and with the use of diclofenac (HR = 0.96 with 
95% CI: 0.81 to 1.15)14 (A). 
However, this study demonstrated that, when compared to 
diclofenac, etoricoxib determined an increase in mean systolic 
blood pressure (when used at a dose of 60 mg/day, it was 
associated with a mean increase in systolic blood pressure of 
3.2 mmHg, 2.5 mmHg, and 1.2 mmHg for 1 month, 12 months, 
and 36 months, respectively), establishing an association 
between treatment dropout and hypertension14-16 (A).
Similar results were also reported in another randomized 
multicenter trial that evaluated the use of rofecoxib at a 
dose of 25 mg/day in patients with type II diabetes mellitus 
and hypertension during treatment for osteoarthritis. It 
was observed that, when compared to the use of rofecoxib, 
ambulatory blood pressure levels measured during 24 h were 
high (mean increase in systolic blood pressure of around 
4.2 ± 1.2 mmHg after six weeks of treatment). When compared 
to the use of naproxen 1.0 g/day, a pressure difference of around 
3.85 mmHg was observed (95% CI: 1.15 to 6.55; p = 0.005)17 (A).
Subsequently, this guideline proposes some considerations 
regarding the use of non-steroidal anti-inflammatory drugs, 
both selective and non-selective, for COX-2, indicated for 
the treatment of primary dysmenorrhea, comparing drugs 
and evaluating mainly the analgesic and adverse effects, 
especially gastrointestinal disorders. It is also very important 
to consider that the comparisons among drugs for the 
treatment of primary dysmenorrhea were performed for a 
short time interval (mean of two days for four consecutive 
menstrual cycles, not exceeding 180 days).
It was therefore not possible to verify of this assessment of 
the aforementioned cardiovascular complications, which lead 
the Brazilian Health Surveillance Agency (Agência Nacional 
de Vigilância Sanitária – ANVISA) to disclose, on February 21, 
2005, the article “Risks and benefits of selective inhibitors of 
COX-2: recommendations by the Technical Chamber of Medi-
cations (Câmara Técnica de Medicamentos – CATEME)”, where 
several general and specific recommendations were made on 
COX-2 selective inhibitors (coxibs) to health professionals and 
consumers, demanding a more stringent oversight by ANVISA18 (D).
Overall recommendations for health professionals:
• The use of coxibs should be considered only for patients 
with significantly increased risk of gastrointestinal bleeding 
risk and no concurrent risk of cardiovascular disease;
• There are no studies demonstrating the safety of these 
drugs in patients younger than 18 years;
• Patients treated with any selective COX-2 inhibitor that 
have ischemic heart disease or cardiovascular disease 
should have their treatment replaced, as soon as possible, 
with a nonselective COX-2 inhibitor;
• For all patients, alternative treatment with nonselective 
COX-2 inhibitors should be considered in the light of an 
individual assessment of risks and benefits of COX-2, par-
ticu larly cardiovascular and gastrointestinal risk factors, 
among others;
• Prescribers should be advised that for all NSAIDs, including 
COX-2, the lowest effective dose should be used for the 
shortest time necessary for treatment;
• For patients whose treatment was replaced by nonselective 
NSAIDs, the possible need for gastroprotective drugs 
should be considered;
• The use of selective inhibitors of COX-2 is contraindicated 
in patients treated with acetylsalicylic acid as an anti-
platelet agent;
Specific recommendations:
• The indication for use of celecoxib in the prophylaxis of 
familial adenomatous polyposis is excluded;
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• The use of valdecoxib and parecoxib are contraindicated 
for patients submitted to surgical myocardial revasculari-
zation procedures; 
• Valdecoxib discontinuation should be considered in the 
presence of skin rash, mucosal lesions, or other symptoms 
suggestive of hypersensitivity, as Stevens-Johnson syn-
dro me and toxic epidermal necrolysis, which are severe 
skin reactions, have been observed with this drug, in 
patients with or without history of allergy to sulfo namides;
• Regarding celecoxib, daily doses > 400 mg should not be 
used, and treatments that consist of the administration of 
daily doses > 200 mg should be reviewed.
CATEME also recommended the following actions to be 
taken by ANVISA:
• To require the manufacturers of drugs classified as 
selective COX-2 inhibitors to follow the ANVISA protocol 
“Change in Package Insert Text Notification”, to add 
recommendations and warnings related to cardiovascular 
risks and other risks discussed in that document;
• To remove from celecoxib’s package insert text the pos si-
bility of using doses > 400 mg;
• To produce an informative document aimed at the pres-
criber/dispenser and other health professionals re com-
mending the rational use of these drugs. The release of this 
document may be made through the professional boards 
and class associations;
• Review the instructions for use of the approved coxibs 
registered in Brazil;
• Review the advertisement on coxibs released by Brazilian 
laboratories. 
Other recommendations, more general, aimed at preven-
ting similar situations in the future, but that do not apply only 
to the case of coxibs were as follows:
• To create and add a symbol to the packaging/labeling/
package insert of innovative drugs indicating that it is a 
new drug and that the knowledge of the safety profile is 
limited, requiring special attention;
• To encourage voluntary reporting of adverse reactions by 
health professionals, particularly for new drugs;
• To promote the rational use of medications; 
• To encourage studies that are independent from the phar-
ma ceutical industry;
• To continuously update systematic reviews of adverse 
events based on published and unpublished data of 
randomized controlled trials and observational studies.
1. Is etoricoxib more effective than naproxen 
in the treatment of women with primary 
dysmenorrhea?
The use of NSAIDs (ibuprofen, naproxen) is the main therapy 
for primary dysmenorrhea; their efficacy results mainly from 
COX-2 inhibition19,20 (D). In turn, etoricoxib is a selective 
inhibitor for this enzyme, showing more than 100-fold selec-
tivity for COX-2 over COX-121 (C).
When evaluating women with a mean age of 30.5 years, 
history of primary dysmenorrhea of moderate to severe 
intensity in at least four of the last six menstrual cycles, with-
out gynecological abnormalities (at physical examination), and 
not allergic to NSAIDs, undergoing therapy with etoricoxib at 
a dose of 120 mg/day, and/or naproxen 550 mg/day for three 
consecutive menstrual cycles, it was observed that the use 
of etoricoxib or naproxen did not show significant difference 
concerning analgesic efficacy assessed by pain relief scores 
for an eight-hour period (TOPAR-8h) (p = 0.326).
When analyzing the necessary time to achieve analgesia, 
it was observed that a single dose of 120 mg of etoricoxib had 
a similar effect to naproxen 550 mg/day (1.5 h versus 1.0 h, 
respectively p = 0.767),22 (A).
Recommendation 1
In women with primary dysmenorrhea, the use of etori-
coxib at the dose of 120 mg/day and naproxen 550 mg/day for 
three consecutive menstrual cycles presented similar results 
regarding analgesic efficacy assessed by pain relief scores for 
an eight-hour period.
2. Is valdecoxib more effective then naproxen 
for the treatment of women with primary 
dysmenorrhea?
Valdecoxib is a NSAID with potent inhibitory action specific 
to COX-2. It has an in vitro selectivity 28,000 times superior for 
COX-2 recombinant enzyme than for COX-123 (C).
In women aged 18 to 35 years, with primary dysmenorrhea 
of moderate to severe intensity (76% and 24%, respectively), 
occurring in at least four of the last six menstrual cycles, 
undergoing therapy with valdecoxib 40 mg/day or 80 mg/day, 
and compared to the use of naproxen 1,100 mg/day, it was 
observed that the analgesia provided by the use of valdecoxib 
at both doses was similar to the analgesia provided by 
naproxen after the administration of the initial dose.
When evaluating pain relief using the scale consisting of 
five points and assessed through TOTPAR (which evaluates 
the achieved analgesia magnitude according to the elapsed 
period), it was observed that treatment with valdecoxib at 
doses of 40 mg/day or 80 mg/day and naproxen 1,100 mg/day 
were similar regarding pain relief in the first eight hours as 
well as after 12 hours (TOTPAR-8h = 19.3, 20.4, and 20.3; and 
TOTPAR-12h = 30.0, 32.1, and 31.2, for valdecoxib 40 mg/day, 
valdecoxib 80 mg/day, and naproxen 1100 mg/day, respectively; 
p < 0.001)24 (A).
The percentage of women that required rescue analgesia 
in the first 12 hours was similar among naproxen 1,100 mg 
and valdecoxib at 40 mg and 80 mg doses (20%, 15%, and 20%), 
respectively24 (A).
Regarding adverse events, similar rates were observed 
between treatment with valdecoxib and naproxen (14.1%, 
17.6%, and 12.9% for valdecoxib 40 mg/day, valdecoxib 80 mg/
day, and naproxen 1,100 mg/day), respectively24 (A).
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Recommendation 2
The use of valdecoxib at doses of 40 mg/day or 80 mg/
day had a similar effect to that of naproxen 1,100 mg/day to 
relieve primary dysmenorrhea, both in the first eight hours 
and after 12 hours; the treatments are well tolerated. 
3. Is rofecoxib more effective than 
naproxen for the treatment of women 
with dysmenorrhea?
Rofecoxib, a selective inhibitor of COX-2 or prostaglandin 
H2 synthase has a low effect on the inhibition of COX-1 
isoenzyme, even at doses > 1,000 mg/day. Clinical trials have 
evaluated its effect at different doses (12.5 mg to 500 mg/day) 
in the treatment of osteoarthritis and rheumatoid arthritis, 
as well as its effectiveness in the treatment of primary 
dysmenorrhea25 (D)7 (B).
When evaluating women with a mean age of 26.9 years 
(SD ± 5.58 years) presenting abdominal pain related to the 
menstrual flow (75% diagnosed as primary dysmenorrhea), 
without systemic diseases or use of medications that may 
promote analgesia (antidepressants, hypnotics, corticos-
teroids), submitted to treatment of dysmenorrhea with rofeco-
xib at doses of 25 mg/day or 50 mg/day, compared to naproxen 
550 mg/day, when pain intensity is evaluated through a 
score with four levels of intensity (0 = no pain, 1 = weak pain, 
2 = moderate pain, 3 = severe pain), no significant difference 
was observed between the treatment of dysmenorrhea using 
naproxen 550 mg/day and rofecoxib 25 mg/day. 
When comparing naproxen with rofecoxib 50 mg/day, 
there was a significant decrease in pain intensity score 
within 30 minutes (p < 0.001), but the same difference was 
not observed after the period of 1 hour. When comparing 
the use of rofecoxib 25 mg/day or 50 mg/day, no significant 
difference was observed between the doses (p > 0.05)26 (B).
Regarding adverse events, especially gastrointestinal, there 
is a greater frequency when using naproxen 550 mg/day (63.6%) 
when compared to rofecoxib 25 mg/day or 50 mg/day26 (B).
Recommendation 3
The use of rofecoxib for the treatment of dysmenorrhea 
(primary or secondary) at doses of 25 mg/day and 50 mg/day 
was shown to be as effective in relieving pain as naproxen 
550 mg/day. When evaluating the rofecoxib doses employed, 
there was no significant difference between 25 mg/day and 
50 mg/day.
4. Is dexibuprofen more effective than 
ibuprofen for the treatment of women 
with primary dysmenorrhea?
Ibuprofen, a racemic mixture of S- and R-enantiomers, is 
a safe and effective NSAID for the relief of pain caused by 
primary dysmenorrhea. Its anti-inflammatory and analgesic 
effects have been attributed mainly to the S-enantiomer, 
called dexibuprofen; the R-enantiomer takes effect only 
after being converted to S-enantiomer27,28 (D).
In women with a mean age of 31.1 years (SD ± 6.7 years) 
and recurrent episodes of primary dysmenorrhea (four 
consecutive menstrual cycles, with pain of moderate 
to severe intensity, distribution of 40.2% and 59.7%, 
respectively), undergoing therapy with dexibuprofen at 
doses of 200 mg/day or 300 mg/day, or 400 mg ibuprofen/
day for three menstrual cycles, it was observed that the 
administration of dexibuprofen 200 mg/day or 300 mg/
day was as effective as ibuprofen 400 mg/day for the relief 
of pain assessed through a scale with four degrees of 
intensity29 (B).
Recommendation 4
Dexibuprofen at doses of 200  mg/day and 300  mg/
day, or 400 mg of ibuprofen/day have equivalent effects 
regarding pain relief in the treatment of primary dys-
menorrhea. 
5. Is lumiracoxib more effective than 
naproxen for the treatment of women 
with primary dysmenorrhea?
In women with a mean age of 28.7 years (SD ± 7.61 years) 
and a positive history of primary dysmenorrhea of moderate 
to severe intensity in at least four of the last six menstrual 
cycles, after exclusion of other causes of dysmenorrhea 
(secondary dysmenorrhea), in the absence of chronic 
abdominal pain, undergoing therapy with lumiracoxib at 
a dose of 200 mg/day, lumiracoxib 200 mg/day followed 
by a further dose of 200 mg on the first day after a period 
of one to 12 hours, with treatment extention for three 
more days if necessary, and the use of naproxen 1,000 mg/
day, no significant difference was observed at the SPID-8h 
evaluation (difference in pain intensity calculated within 
the eight-hour period after treatment administration, 
in which pain intensity is assessed either through the 
four-point scale or through of the visual analogue scale) 
for the use of naproxen and two lumiracoxib administration 
regimens (12.07, 12.0, and 12.11 for lumiracoxib 200 mg/
day, lumiracoxib 200 mg/day combined with another dose 
of 200 mg on the first day, and naproxen 1000 mg/day, 
respectively; p < 0.00130 (B).
Regarding pain relief, assessed through the five-point 
scale with for a period of 8 and 12 hours (TOTPAR-8h and 
TOTPAR-12h), no significant difference was observed between 
the two regimens with lumiracoxib or between these schemes 
and naproxen (19.65, 19.39, and 19.56 for lumiracoxib 200 mg/
day, lumiracoxib 200 mg/day associated with a further dose 
of 200 mg, and naproxen 1,000 mg/day, respectively, in the 
period of eight hours; and 29.23, 30.59, and 30.35, for the 
period of 12 hours, respectively)30 (B).
Regarding adverse events (nausea, headache, abdominal 
pain, diarrhea), it was observed that the treatments were 
well tolerated (19%, 19.7%, and 22.6% for lumiracoxib 
200  mg/day, lumiracoxib 200  mg/day combined with 
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a further dose of 200 mg, and naproxen 1,000 mg/day, 
respectively)30 (B).
Recommendation 5
The use of lumiracoxib at a dose of 200 mg/day, with or 
without a new dose of 200 mg on the first day of treatment 
in women with primary dysmenorrhea of moderate to 
severe intensity had an analgesic efficacy similar to that of 
naproxen. 
6. Is dexketoprofen more effective than 
ketoprofen in the treatment of primary 
dysmenorrhea?
Dexketoprofen is an S (+) enantiomer of ketoprofen, which 
is a racemic compound resulting from the mixture of R- 
and S-enantiomers. As in derivatives of propionic acid, S (+) 
enantiomer is the compound responsible for the inhibitory 
effect of ketoprofen on COX isoenzymes31 (C). In animal 
models, it has been demonstrated that the anti-inflammatory 
potency of dexketoprofen is equivalent to twice the dose 
of ketoprofen. The R (–) enantiomer exhibits a much lower 
potency, and its analgesic action apparently occurs only 
through its metabolic inversion to the S (+) enantiomer27 (D). 
Thus, the selective administration of the active enantiomer, 
S-enantiomer, apparently has advantages over the racemic 
mixture.
In women with a mean age of 24.6 years (SD ± 5.2 years) 
diagnosed as having primary dysmenorrhea (after ruling 
out secondary causes of dysmenorrhea), of moderate to 
severe intensity, lasting for at least four months, submitted 
to therapy for three days in four consecutive menstrual 
cycles with dexketoprofen at doses of 50 mg/day or 100 mg/
day, or ketoprofen 200 mg/day, it was observed that in the 
TOTPAR-6h evaluation (assessed by verbal scale of pain relief 
consisting of five points, six hours after receiving the drug), 
the active treatments did not present significant difference 
(15.8 ± 7.4, 15.9 ± 6.9, and 17.7 ± 5.9 for dexketoprofen 50 mg/
day, dexketoprofen 100 mg/day, and ketoprofen 200 mg/day, 
respectively, p < 0.05). 
Regarding pain intensity assessed by the SPID-6h 
(difference in pain intensity after treatment administration, 
assessed through verbal pain scale consisting of four points 
and the visual analogue scale – VAS 0-100 mm), 6 hours after 
treatment, a significant difference was not observed between 
treatments (8.6 ± 5.3, 8.0 ± 5.2, and 9.3 ± 4.4 for dexketoprofen 
50  mg/day, dexketoprofen 100  mg/day, and ketoprofen 
200 mg/day, respecti vely32 (A).
Regarding adverse events, no significant difference was 
observed between treatments32 (A).
Recommendation 6
When analyzing the scores for pain relief, no significant 
analgesic difference was observed between treatments; 
dexketoprofen at doses of 50 mg/day and 100 mg/day were 
shown to be as effective in relieving pain as ketoprofen 
200 mg/day.
7. Is bromfenac more effective than naproxen 
for the treatment of women with primary 
dysmenorrhea?
Bromfenac, a 2-amino-3 phenyl acetic acid derivative, is a 
potent PGF2a-inhibitor that has shown analgesic properties in 
animal models33 (C). Pharmacodynamics studies have shown 
that, after its administration, the drug reaches maximum 
concentration within a time period ranging from 20  to 
40 minutes, and its analgesic and anti-inflammatory actions 
persist for over 24 hours.
When evaluating women of a mean age of 32.2 years 
(SD  ±  7.3  years) with primary dysmenorrhea (positive 
dysmenorrhea history in at least four consecutive months, 
with moderate to severe pain intensity), undergoing therapy 
with bromfenac at doses of 50 mg/day or 10 mg/day, and 
naproxen 550 mg/day over the course of one to three days 
for a period of five months, it was observed that the doses of 
10 mg/day and 50 mg/day of bromfenac were as effective as 
naproxen 550 mg/day for pain relief when assessed through 
TOPAR-3h and 6h (total score of pain relief after the first dose 
of medication as well as three to six hours after treatment, 
p < 0.001)34 (B).
Recommendation 7
The use of bromfenac at doses of 10 mg/day and 50 mg/
day is as effective in relieving pain of primary dysmenorrhea 
as naproxen 550 mg/day.
8. Is piroxicam more effective than ibuprofen 
for the treatment of primary dysmenorrhea?
Piroxicam, which belongs to the oxican group, has advantages 
regarding treatment adherence over other anti-inflammatory 
due to its prolonged serum half-life, which allows for a single 
daily dose administration35 (D).
When evaluating women of a mean age of 24.4 years, with 
primary dysmenorrhea of moderate to severe intensity, with 
at least six months of history, after ruling out secondary 
causes for secondary dysmenorrhea, undergoing treatment 
for a minimum of three and maximum of five days, with 
piroxicam 20 mg/day for five days; piroxicam 40 mg/day on 
the first day, followed by administration of piroxicam 20 mg/
day from the second to the fifth days; piroxicam 40 mg/
day on the first two days followed by piroxicam 20 mg/
day from the third to fifth days; and ibuprofen 1,600 mg/
day, it was observed that the relief of overall discomfort 
measured within 24 hours after treatment administration 
and evaluated through the five point scale (0 = none, 1 = mild, 
2 = moderate, 3 = severe) showed no significant difference 
between treatments. 
When analyzing the use of rescue medication for the 
treatment of pain within the first 24 hours, it was observed 
that the administration of piroxicam 40 mg/day on the 
first two days followed by piroxicam 20 mg/day from the 
third to fifth day significantly reduced the need for drug 
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supplementation compared to women treated with piroxicam 
20 mg/day for five days (p = 0.035)36 (A).
Recommendation 8
In women with primary dysmenorrhea treated with a single 
daily dose of piroxicam (40 mg/day for two days followed 
by 20 mg/day for three more days; 40 mg/day for one day, 
followed by 20 mg/day for four more days; and 20 mg/day 
for five days) it was observed that discomfort and pain relief 
within 24 hours is comparable to the administration of 400 mg 
ibuprofen four times a day.
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